-transparent.png){kind=logo}
cis-Dichlorodiammineplatinum(II) was given to 13 patients with metastatic sarcomas following failure in two previous chemotherapy protocols. Two of these patients had complete regression which lasted 6 months in one patient and is still present after 8 months in the other. One patient had a greater than 50% regression which lasted 5 months. Three patients had disease stabilization for 2 months each. cis-Dichlorodiammineplatinum(II), as a single agent, was well-tolerated with no significant renal or auditory toxicity.
Related Publications
C P Karakousis, and
O A Holtermann, and
E D Holyoke
January 1979,
Cancer treatment reports,
C P Karakousis, and
O A Holtermann, and
E D Holyoke
August 1983,
Archives of surgery (Chicago, Ill. : 1960),
C P Karakousis, and
O A Holtermann, and
E D Holyoke
January 1997,
Cancer treatment and research,
C P Karakousis, and
O A Holtermann, and
E D Holyoke
January 1979,
Cancer treatment reports,
C P Karakousis, and
O A Holtermann, and
E D Holyoke
April 1982,
Gan to kagaku ryoho. Cancer & chemotherapy,
C P Karakousis, and
O A Holtermann, and
E D Holyoke
January 1979,
Cancer treatment reports,
C P Karakousis, and
O A Holtermann, and
E D Holyoke
January 1995,
Clinical orthopaedics and related research,
C P Karakousis, and
O A Holtermann, and
E D Holyoke
April 2021,
Cancers,
C P Karakousis, and
O A Holtermann, and
E D Holyoke
January 1982,
European journal of cancer & clinical oncology,
C P Karakousis, and
O A Holtermann, and
E D Holyoke
January 1979,
Cancer treatment reports,
